Further reports from 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July 2003
1 October 2003. Related: Conference reports.
Conference reports
New atazanavir information
1 October 2003. Related: Conference reports, Antiretrovirals.
Boosted PI therapy antiretrovirals in treatment-experienced patients: SQV/r, ATV, ATV/r
1 October 2003. Related: Conference reports, Antiretrovirals.
HIV viral dynamics: viral fitness, genetic diversity, progression, co-receptor use
1 October 2003. Related: Conference reports, Basic science and immunology, Virology.
Pulmonary hypertension: finally a treatment trial!
1 October 2003. Related: Conference reports, Virology.
XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003
1 September 2003. Related: Conference reports, Drug resistance.
Transmission of drug resistance – at 11% in Europe and 17% in the UK
1 September 2003. Related: Conference reports, HIV prevention and transmission, Drug resistance.
HIV coinfection, reinfection and superinfection
1 September 2003. Related: Conference reports, Hepatitis coinfection, HIV prevention and transmission, Drug resistance.
Single-dose nevirapine resistance in over 75% of mothers
1 September 2003. Related: Conference reports, Women's health, Pregnancy, Drug resistance.
Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’
1 September 2003. Related: Conference reports, Drug resistance.
Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample
1 September 2003. Related: Conference reports, Drug resistance.
Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing
1 September 2003. Related: Conference reports, Drug resistance.
Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations
1 September 2003. Related: Conference reports, Drug resistance.
Replicative capacity results complicated by minority wild-type virus
1 September 2003. Related: Conference reports, Virology, Drug resistance.
Tenofovir, resistance and K65R and concomitant nucleosides
1 September 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Response to STI is determined by virus rather than immunological response
1 September 2003. Related: Conference reports, Drug resistance.
Why resistance rarely develops with viral suppression <50 copies/mL
1 September 2003. Related: Conference reports, Drug resistance.
Long-term persistence of distinct mutations in genital tract
1 September 2003. Related: Conference reports, Women's health, Drug resistance.
5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
Underlying mechanisms: adipocytes and cytokines
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications, Basic science and immunology.
More mitochondrial DNA depletion
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
IMT and cardiovascular risk
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
Reduced bone mineral density in HIV-positive women
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
Rosiglitazone with insulin resistance
1 September 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Additional benefits of exercise with metformin
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Weight, diabetes, metabolic complications.
Facial fat loss – measuring and treatment
1 September 2003. Related: Conference reports, Treatment access, Weight, diabetes, metabolic complications.
Uridine treatment for mitochondrial toxicity
1 September 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Breast enlargement in men and testosterone treatment
1 September 2003. Related: Conference reports, Weight, diabetes, metabolic complications.
Severe efavirenz psychotic events
1 September 2003. Related: Conference reports, Side effects.
Treatment interruption: a real choice
1 September 2003. Related: Conference reports, Treatment strategies, Weight, diabetes, metabolic complications.
2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris
1 September 2003. Related: Conference reports.
Nevirapine and MTCT: the single-dose backlash
1 September 2003. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, Paediatric care.
Triple nucleoside combinations fail patients again
1 September 2003. Related: Conference reports, Antiretrovirals.
Nucleoside-sparing regimens
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual boosted PIs in salvage therapy
1 September 2003. Related: Conference reports, Antiretrovirals.
BMS reports on atazanavir efficacy and safety in treatment experienced patients
1 September 2003. Related: Conference reports, Antiretrovirals.
Unsupervised treatment interruptions are associated with increased risk of AIDS or death
1 September 2003. Related: Conference reports, Antiretrovirals.
Uridine as a potential treatment for NRTI related mitochondrial toxicity
1 September 2003. Related: Conference reports, PK and drug interactions, Side effects.
Long term exposure to nucleoside analogues and peripheral nerve function
1 September 2003. Related: Conference reports, Side effects.
Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy
1 September 2003. Related: Conference reports, Antiretrovirals, Side effects.
First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age
1 September 2003. Related: Conference reports, Basic science and immunology.
Lessons learned from early HAART in acute HIV infection
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
CD4 cell reconstitution is significantly slower in older patients
1 September 2003. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Pharmacology studies at the 2nd IAS conference
1 September 2003. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Studies highlight problems of rectal disease in HIV-positive patients
1 September 2003. Related: Conference reports, Coinfections and complications.
9th Annual British HIV Association Conference (BHIVA), 24-26 April 2003, Manchester
1 June 2003. Related: Conference reports.
UK 2003 audit and national standards of care
1 June 2003. Related: Conference reports.
Outline of changes to UK 2003 guidelines for treating HIV in adults
1 June 2003. Related: Conference reports, Guidelines.
Gender differences in rates and reasons for stopping treatment
1 June 2003. Related: Conference reports, Treatment strategies, Women's health.
Maternal health, transmission and fertility
1 June 2003. Related: Conference reports, Women's health, Pregnancy.
Women: sexual function and relationships
1 June 2003. Related: Conference reports, Women's health, Side effects.
Paediatrics: neurological and developmental outcomes
1 June 2003. Related: Conference reports, Paediatric care, Coinfections and complications.
The impact of migration, race and ethnic diversity on healthcare delivery and clinical outcomes in the UK
1 June 2003. Related: Conference reports, Treatment access, Women's health.
High levels of gout may be linked to HAART
1 June 2003. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
4th International Workshop on Clinical Pharmacology of HIV Therapy, 27-29 March 2003, Cannes, France
1 May 2003. Related: Conference reports, PK and drug interactions.
Can low NVP plasma concentrations explain the results seen in the EFV and NVP containing arms of the NARVAL study?
1 May 2003. Related: Conference reports, PK and drug interactions.
Up to one third of patients receiving standard doses of NNRTIs may be being underdosed
1 May 2003. Related: Conference reports, PK and drug interactions.
Nelfinavir concentrations are significantly higher in HIV/HCV co-infected patients with cirrhosis
1 May 2003. Related: Conference reports, PK and drug interactions.
Less diarrhoea and bioequivalence with the new nelfinavir 625mg tablet
1 May 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions, Side effects.
The potential for probenecid to have a serious interaction with HIV-1 protease inhibitors
1 May 2003. Related: Conference reports, PK and drug interactions, Side effects.
PK studies reveal significant sex/gender differences
1 May 2003. Related: Conference reports, Women's health, PK and drug interactions.
Pregnancy-related PK studies
1 May 2003. Related: Conference reports, Pregnancy, PK and drug interactions.
New test to measure intracellular levels of nucleosides
1 May 2003. Related: Conference reports, PK and drug interactions.
Case studies for therapeutic drug monitoring (TDM)
1 May 2003. Related: Conference reports, PK and drug interactions.